M J Benvenga
Overview
Explore the profile of M J Benvenga including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
83
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Menezes M, Santini M, Benvenga M, Marek G, Merchant K, Mikkelsen J, et al.
Neurosci J
. 2015 Aug;
2013:736439.
PMID: 26317098
Metabotropic glutamate 2/3 (mGlu2/3) receptors have emerged as potential therapeutic targets due to the ability of mGlu2/3 receptor agonists to modulate excitatory transmission at specific synapses. LY354740 and LY379268 are...
2.
Gehlert D, Dreshfield L, Tinsley F, Benvenga M, Gleason S, Fuller R, et al.
J Pharmacol Exp Ther
. 1998 Oct;
287(1):122-7.
PMID: 9765330
The compound, LY368975 ((R)-thionisoxetine) is a potent and selective inhibitor of the norepinephrine (NE) reuptake site. We evaluated the in vivo properties of LY368975 in various animal models. In mice,...
3.
Moore N, Leander J, Benvenga M, Gleason S, Shannon H
J Clin Psychiatry
. 1997 Jan;
58 Suppl 10:37-44.
PMID: 9265915
Background: In this paper, we review the behavioral pharmacology of olanzapine and compare it to its in vitro profile and to clozapine and a number of other antipsychotic agents, and...
4.
Benvenga M, Leander J
Behav Pharmacol
. 1996 Nov;
7(6):540-550.
PMID: 11224451
Anxiety is a phenomenon that has many different manifestations. In order to test whether or not agents targeted to treat anxiety may have the properties necessary to treat differing types...
5.
Benvenga M, Ornstein P, Leander J
J Pharmacol Exp Ther
. 1995 Oct;
275(1):164-70.
PMID: 7562545
Behavioral effects of the selective 2-amino-3-(5-methyl-3-hydroxyisoxazol-4- yl)propanoic acid (AMPA) antagonist LY293558, along with its racemate (LY215490) and opposing enantiomer (LY293559) were evaluated in pigeons. When responding was maintained under a...
6.
Benvenga M, Leander J
Psychopharmacology (Berl)
. 1995 May;
119(2):133-8.
PMID: 7544900
The effects of olanzapine [LY 170053; 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2, 3b] [1,5]benzodiazepine), a potential atypical antipsychotic, were determined in pigeons whose keypeck responding was punished. These effects were compared to the anxiolytic agents...
7.
Foreman M, Fuller R, Leander J, Benvenga M, Wong D, Nelson D, et al.
J Pharmacol Exp Ther
. 1993 Oct;
267(1):58-71.
PMID: 8229788
LY228729 is a conformationally restricted tryptamine derivative with a carboxamide serving as a protophilic group to mimic the hydroxyl in serotonin (5-HT). LY228729 has high affinity for the 5-HT1A receptor,...
8.
Benvenga M, Leander J
Eur J Pharmacol
. 1993 Aug;
239(1-3):249-52.
PMID: 8223903
The novel 5-HT1A receptor agonist, LY228729, was tested to see if it would produce antidepressant-like behavioural effects in the rodent forced swim model. The tricyclic antidepressant, imipramine, as well as...
9.
An in vivo alpha-2 assay reversal of opioid-induced muscular rigidity and neuroleptic-induced ptosis
Benvenga M, Del Vecchio R, Capacchione J, Jerussi T
J Pharmacol Toxicol Methods
. 1992 Mar;
27(1):45-50.
PMID: 1349839
A method is described to detect selective alpha-2 adrenergic agonists in vivo. Palpebral ptosis is induced in rats by the neuroleptic agent haloperidol (Hal), or by tetrabenazine (TBZ) methanesulfonate. Twenty...
10.
Bagley J, Kudzma L, Lalinde N, Colapret J, Huang B, Lin B, et al.
Med Res Rev
. 1991 Jul;
11(4):403-36.
PMID: 1875771
No abstract available.